- Home
- MYSE vs ICU Comparison
MYSE vs ICU Comparison
Compare MYSE & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | ICU |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 13.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYSE | ICU |
|---|---|---|
| Price | $2.67 | $3.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.0K | 69.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $550.00 | ★ $1,234,000.00 |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 26.15 | ★ 814.07 |
| 52 Week Low | $1.31 | $0.22 |
| 52 Week High | $5.77 | $5.38 |
Technical Indicators
Market Signals| Indicator | MYSE | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 38.83 |
| Support Level | $1.66 | $2.96 |
| Resistance Level | $2.83 | $3.50 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 56.00 | 3.66 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.